.Pharmacolibrary.Drugs.P_AntiparasiticProductsInsecticidesAndRepellents.P01C_AgentsAgainstLeishmaniasisAndTrypanosomiasis.P01CC01_Nifurtimox.Nifurtimox

Information

Nifurtimox is a nitrofuran derivative used primarily for the treatment of Chagas disease (American trypanosomiasis), caused by Trypanosoma cruzi. It has antiparasitic activity and is sometimes used off-label for other trypanosomal diseases. Nifurtimox has been approved for use in several countries, but is often reserved for cases where benznidazole is not available or appropriate.

Pharmacokinetics

Pharmacokinetic parameters in healthy adults after oral administration; data primarily from non-compartmental and compartmental PK studies.

References

1. Amilon, C, et al., & Jansson-Löfmark, R (2022). Population Pharmacodynamic Modeling of Eflornithine-Based Treatments Against Late-Stage Gambiense Human African Trypanosomiasis and Efficacy Predictions of L-eflornithine-Based Therapy. The AAPS journal 24(3) 48–None. DOI:10.1208/s12248-022-00693-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35338410

2. Del Moral Sanchez, JM, et al., & Bermejo, M (2018). Biopharmaceutical optimization in neglected diseases for paediatric patients by applying the provisional paediatric biopharmaceutical classification system. British journal of clinical pharmacology 84(10) 2231–2241. DOI:10.1111/bcp.13650 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29846973

Revisions

• 06/2025 initial generated model